CURRENT
ISSUE
1592
February 24, 2020

Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks to achieve a substantial benefit. Following successful treatment of a first major depressive episode, antidepressant treatment should be continued at the same dose for at least 4-9 months to consolidate recovery. In patients with recurrent depressive episodes, long-term maintenance treatment can reduce the risk of relapse.1

A selective serotonin reuptake inhibitor (SSRI) is generally used for initial treatment of major depressive disorder. A serotonin-norepinephrine reuptake inhibitor (SNRI), bupropion (Wellbutrin SR, and others), and mirtazapine (Remeron, and generics) are reasonable...  Continue reading

More from Issue 1592
Previous Issue: 1591      February 10, 2020
Coming Soon
Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis
Lasmiditan (Reyvow) for Treatment of Migraine
Palforzia for Treatment of Peanut Allergy
Drugs for Irritable Bowel Syndrome
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
Featured Article
FROM
ISSUE
1591
Icosapent ethyl (Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (≥150 mg/dL) who have either established cardiovascular disease (CVD) or diabetes and ≥2 additional risk factors for CVD. It is the only omega-3 polyunsaturated fatty acid (PUFA) product to be approved in the ... Continue reading